Literature DB >> 15735670

Expression of EGF-family receptors and amphiregulin in multiple myeloma. Amphiregulin is a growth factor for myeloma cells.

Karène Mahtouk1, Dirk Hose, Thierry Rème, John De Vos, Michel Jourdan, Jérôme Moreaux, Geneviève Fiol, Marc Raab, Eric Jourdan, Véronique Grau, Marion Moos, Hartmut Goldschmidt, Marion Baudard, Jean François Rossi, Friedrich W Cremer, Bernard Klein.   

Abstract

A hallmark of plasma cells is the expression of syndecan-1, which has major functions in epithelial cells, in particular as the coreceptor of heparin-binding growth factors. We previously found that heparin-binding epidermal growth factor-like growth factor (HB-EGF) is a growth factor for malignant plasma cells. As amphiregulin (AREG) is another heparin-binding factor of the EGF family, we investigated its role in multiple myeloma (MM). Using Affymetrix DNA microarrays, we show here that the AREG gene was expressed by purified primary myeloma cells from 65 patients and that the expression was higher than in normal bone marrow (BM) plasma cells or plasmablastic cells. AREG stimulated IL-6 production and growth of BM stromal cells. Using real-time reverse transcriptase-polymerase chain reaction, we found that MM cells expressed ErbB receptors and that AREG promoted their growth. Furthermore, PD169540 (a pan-ErbB inhibitor) and IRESSA (an ErbB1-specific inhibitor) induced apoptosis of primary myeloma cells from 10/14 and 4/14 patients, respectively, and there was a synergistic effect with dexamethasone. Altogether, our data provide strong evidence that AREG plays an important role in the biology of MM and emphasize the advantages of using ErbB inhibitors, which might target myeloma cells as well as the tumor environment.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15735670      PMCID: PMC2408676          DOI: 10.1038/sj.onc.1208536

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  37 in total

1.  Epidermal growth factor and betacellulin mediate signal transduction through co-expressed ErbB2 and ErbB3 receptors.

Authors:  M Alimandi; L M Wang; D Bottaro; C C Lee; A Kuo; M Frankel; P Fedi; C Tang; M Lippman; J H Pierce
Journal:  EMBO J       Date:  1997-09-15       Impact factor: 11.598

2.  Topography of amphiregulin expression in cultured human keratinocytes: colocalization with the epidermal growth factor receptor and CD44.

Authors:  N Nylander; L T Smith; R A Underwood; M Piepkorn
Journal:  In Vitro Cell Dev Biol Anim       Date:  1998-02       Impact factor: 2.416

3.  Possible role of coexpression of CD9 with membrane-anchored heparin-binding EGF-like growth factor and amphiregulin in cultured human keratinocyte growth.

Authors:  S Inui; S Higashiyama; K Hashimoto; M Higashiyama; K Yoshikawa; N Taniguchi
Journal:  J Cell Physiol       Date:  1997-06       Impact factor: 6.384

4.  Paracrine rather than autocrine regulation of myeloma-cell growth and differentiation by interleukin-6.

Authors:  B Klein; X G Zhang; M Jourdan; J Content; F Houssiau; L Aarden; M Piechaczyk; R Bataille
Journal:  Blood       Date:  1989-02       Impact factor: 22.113

5.  CD9 antigen interacts with heparin-binding EGF-like growth factor through its heparin-binding domain.

Authors:  T Sakuma; S Higashiyama; S Hosoe; S Hayashi; N Taniguchi
Journal:  J Biochem       Date:  1997-08       Impact factor: 3.387

6.  Reproducible obtaining of human myeloma cell lines as a model for tumor stem cell study in human multiple myeloma.

Authors:  X G Zhang; J P Gaillard; N Robillard; Z Y Lu; Z J Gu; M Jourdan; J M Boiron; R Bataille; B Klein
Journal:  Blood       Date:  1994-06-15       Impact factor: 22.113

7.  IFN-alpha induces autocrine production of IL-6 in myeloma cell lines.

Authors:  M Jourdan; X G Zhang; M Portier; J M Boiron; R Bataille; B Klein
Journal:  J Immunol       Date:  1991-12-15       Impact factor: 5.422

8.  Measurement of whole body interleukin-6 (IL-6) production: prediction of the efficacy of anti-IL-6 treatments.

Authors:  Z Y Lu; H Brailly; J Wijdenes; R Bataille; J F Rossi; B Klein
Journal:  Blood       Date:  1995-10-15       Impact factor: 22.113

9.  Interleukin-10 is a proliferation factor but not a differentiation factor for human myeloma cells.

Authors:  Z Y Lu; X G Zhang; C Rodriguez; J Wijdenes; Z J Gu; B Morel-Fournier; J L Harousseau; R Bataille; J F Rossi; B Klein
Journal:  Blood       Date:  1995-05-01       Impact factor: 22.113

10.  Adhesion of human myeloma-derived cell lines to bone marrow stromal cells stimulates interleukin-6 secretion.

Authors:  H Uchiyama; B A Barut; A F Mohrbacher; D Chauhan; K C Anderson
Journal:  Blood       Date:  1993-12-15       Impact factor: 22.113

View more
  47 in total

Review 1.  Microarray-based understanding of normal and malignant plasma cells.

Authors:  John De Vos; Dirk Hose; Thierry Rème; Karin Tarte; Jérôme Moreaux; Karéne Mahtouk; Michel Jourdan; Hartmut Goldschmidt; Jean-François Rossi; Friedrich W Cremer; Bernard Klein
Journal:  Immunol Rev       Date:  2006-04       Impact factor: 12.988

2.  Gene expression of anti- and pro-apoptotic proteins in malignant and normal plasma cells.

Authors:  Michel Jourdan; Thierry Reme; Hartmut Goldschmidt; Geneviève Fiol; Véronique Pantesco; John De Vos; Jean-François Rossi; Dirk Hose; Bernard Klein
Journal:  Br J Haematol       Date:  2009-01-08       Impact factor: 6.998

3.  Role of decorin in the antimyeloma effects of osteoblasts.

Authors:  Xin Li; Angela Pennisi; Shmuel Yaccoby
Journal:  Blood       Date:  2008-04-24       Impact factor: 22.113

4.  Heparan sulphate proteoglycans are essential for the myeloma cell growth activity of EGF-family ligands in multiple myeloma.

Authors:  K Mahtouk; F W Cremer; T Rème; M Jourdan; M Baudard; J Moreaux; G Requirand; G Fiol; J De Vos; M Moos; P Quittet; H Goldschmidt; J-F Rossi; D Hose; B Klein
Journal:  Oncogene       Date:  2006-05-29       Impact factor: 9.867

5.  Epidermal growth factor receptor controls glycogen phosphorylase in T cells through small GTPases of the RAS family.

Authors:  Francisco Llavero; Miriam Luque Montoro; Alazne Arrazola Sastre; David Fernández-Moreno; Hadriano M Lacerda; Luis A Parada; Alejandro Lucia; José L Zugaza
Journal:  J Biol Chem       Date:  2019-01-15       Impact factor: 5.157

6.  Expression of genes encoding for proteins involved in heparan sulphate and chondroitin sulphate chain synthesis and modification in normal and malignant plasma cells.

Authors:  Caroline Bret; Dirk Hose; Thierry Reme; Anne-Catherine Sprynski; Karène Mahtouk; Jean-François Schved; Philippe Quittet; Jean-François Rossi; Hartmut Goldschmidt; Bernard Klein
Journal:  Br J Haematol       Date:  2009-03-02       Impact factor: 6.998

7.  Growth factors in multiple myeloma: a comprehensive analysis of their expression in tumor cells and bone marrow environment using Affymetrix microarrays.

Authors:  Karène Mahtouk; Jérôme Moreaux; Dirk Hose; Thierry Rème; Tobias Meissner; Michel Jourdan; Jean François Rossi; Steven T Pals; Hartmut Goldschmidt; Bernard Klein
Journal:  BMC Cancer       Date:  2010-05-13       Impact factor: 4.430

8.  Tight Junction Protein 1 Modulates Proteasome Capacity and Proteasome Inhibitor Sensitivity in Multiple Myeloma via EGFR/JAK1/STAT3 Signaling.

Authors:  Xing-Ding Zhang; Veerabhadran Baladandayuthapani; Heather Lin; George Mulligan; Bin Li; Dixie-Lee W Esseltine; Lin Qi; Jianliang Xu; Walter Hunziker; Bart Barlogie; Saad Z Usmani; Qing Zhang; John Crowley; Antje Hoering; Jatin J Shah; Donna M Weber; Elisabet E Manasanch; Sheeba K Thomas; Bing-Zong Li; Hui-Han Wang; Jiexin Zhang; Isere Kuiatse; Jin-Le Tang; Hua Wang; Jin He; Jing Yang; Enrico Milan; Simone Cenci; Wen-Cai Ma; Zhi-Qiang Wang; Richard Eric Davis; Lin Yang; Robert Z Orlowski
Journal:  Cancer Cell       Date:  2016-04-28       Impact factor: 31.743

9.  Bone morphogenic protein 6: a member of a novel class of prognostic factors expressed by normal and malignant plasma cells inhibiting proliferation and angiogenesis.

Authors:  A Seckinger; T Meissner; J Moreaux; H Goldschmidt; G M Fuhler; A Benner; M Hundemer; T Rème; J D Shaughnessy; B Barlogie; U Bertsch; J Hillengass; A D Ho; V Pantesco; A Jauch; J De Vos; J F Rossi; T Möhler; B Klein; D Hose
Journal:  Oncogene       Date:  2009-08-31       Impact factor: 9.867

10.  Amphiregulin enhances regulatory T cell-suppressive function via the epidermal growth factor receptor.

Authors:  Dietmar M W Zaiss; Jorg van Loosdregt; Andrea Gorlani; Cornelis P J Bekker; Andrea Gröne; Maria Sibilia; Paul M P van Bergen en Henegouwen; Rob C Roovers; Paul J Coffer; Alice J A M Sijts
Journal:  Immunity       Date:  2013-01-17       Impact factor: 31.745

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.